No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

• Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
• Laboratorios Farmaceuticos Rovi, S.A.
• Hanmi Pharm. Co., Ltd.
• Jilin Aodong Pharmaceutical Group Co., Ltd.
• Walvax Biotechnology Co., Ltd.
• China National Medicines Corporation Ltd.
• Sumitomo Pharma Co., Ltd.
• Tasly Pharmaceutical Group Co., Ltd